 |
5 Diseases |  |
0 Trials |
|
0 Trials |  |
30 News |  |
- | Zemimet SR (gemigliptin/metformin sustained release) / LG Chem, NN1213 / Novo Nordisk
Trial completion, Trial completion date, Combination therapy: INTESTINE: Initial Combination of Gemigliptin and Metformin on Microbiota Change (clinicaltrials.gov) - Mar 30, 2021
P=N/A, N=70, Completed, Sponsor: Seoul National University Bundang Hospital
Active, not recruiting --> Completed | Trial completion date: Dec 2021 --> Mar 2021
- || Zemimet SR (gemigliptin/metformin sustained release) / LG Chem
Trial completion, Enrollment change, Trial completion date: Bioequivalence Study for Fixed Dose Combination Zemimet (clinicaltrials.gov) - Feb 9, 2021
P1, N=40, Completed, Sponsor: LG Chem
Active, not recruiting --> Completed | Trial completion date: Dec 2021 --> Mar 2021 Not yet recruiting --> Completed | N=60 --> 40 | Trial completion date: Dec 2020 --> Sep 2020
- || metformin / Generic mfg., Zemimet SR (gemigliptin/metformin sustained release) / LG Chem
Clinical, PK/PD data, Journal: Pharmacokinetics and pharmacodynamics of a fixed-dose combination of gemigliptin/metformin sustained release 25/500 mg compared to the loose combination in healthy male subjects. (Pubmed Central) - Apr 11, 2020
P1
In conclusion, the PK/PD characteristics of gemigliptin and metformin were similar in FDC tablets and loose combination both in fasted and fed states. ClinicalTrials.gov Identifier: NCT03355014.
- | Zemimet SR (gemigliptin/metformin sustained release) / LG Chem, NN1213 / Novo Nordisk
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy: INTESTINE: Initial Combination of Gemigliptin and Metformin on Microbiota Change (clinicaltrials.gov) - Apr 8, 2020
P=N/A, N=70, Active, not recruiting, Sponsor: Seoul National University Bundang Hospital
ClinicalTrials.gov Identifier: NCT03355014. Recruiting --> Active, not recruiting | Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2019 --> Dec 2020
- ||| Zemimet SR (gemigliptin/metformin sustained release) / LG Chem
New P1 trial: Bioequivalence Study for Fixed Dose Combination Zemimet (clinicaltrials.gov) - Mar 23, 2020
P1, N=60, Not yet recruiting, Sponsor: LG Chem
- | Zemimet SR (gemigliptin/metformin sustained release) / LG Chem, NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date, Combination therapy: INTESTINE: Initial Combination of Gemigliptin and Metformin on Microbiota Change (clinicaltrials.gov) - Oct 8, 2019
P=N/A, N=70, Recruiting, Sponsor: Seoul National University Bundang Hospital
Recruiting --> Active, not recruiting | Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2019 --> Dec 2020 Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Apr 2019 --> Dec 2019
- | Zemimet SR (gemigliptin/metformin sustained release) / LG Chem
Clinical, PK/PD data, Journal: Pharmacokinetic Interactions Between Gemigliptin and Metformin, and Potential Differences in the Pharmacokinetic Profile of Gemigliptin Between the Mexican and Korean Populations: A Randomized, Open-Label Study in Healthy Mexican Volunteers. (Pubmed Central) - Sep 20, 2019
P1
Considering the flat effect-concentration curve and wide therapeutic range of gemigliptin, the pharmacokinetic profile of gemigliptin observed in healthy Mexican and Korean subjects suggests that gemigliptin use in Mexican patients may be associated with outcomes, in terms of efficacy and tolerability, similar to those observed in the Korean population. ClinicalTrials.gov identifier: NCT03310749.
- | Zemimet SR (gemigliptin/metformin sustained release) / LG Chem
New P1 trial: Food-effect Bioavailability of Fixed Dose Combination Zemimet (clinicaltrials.gov) - Aug 28, 2019
P1, N=24, Not yet recruiting, Sponsor: LG Chem
- | Zemimet SR (gemigliptin/metformin sustained release) / LG Chem
New P1 trial: Bioequivalence Study for Gemigliptin/Metformin 50/1000 mg and Coadministration of Gemigliptin 50 mg and Metformin 1000 mg. (clinicaltrials.gov) - Aug 7, 2019
P1, N=24, Not yet recruiting, Sponsor: LG Chem
- | Zemimet SR (gemigliptin/metformin sustained release) / LG Chem
PK/PD data, Journal: Pharmacokinetic comparison of gemigliptin 50 mg and metformin 500 mg as a fixed-dose combination and loose combination. (Pubmed Central) - Aug 7, 2019
ClinicalTrials.gov identifier: NCT03310749. When comparing the AUC and C of gemigliptin, LC15-0636, and metformin, the 90% CIs were all within the range of 0.8 - 1.25, which is the commonly accepted range for evaluating bioequivalence.
- | Zemimet SR (gemigliptin/metformin sustained release) / LG Chem, NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date, Combination therapy: INTESTINE: Initial Combination of Gemigliptin and Metformin on Microbiota Change (clinicaltrials.gov) - Oct 24, 2018
P=N/A, N=70, Recruiting, Sponsor: Seoul National University Bundang Hospital
When comparing the AUC and C of gemigliptin, LC15-0636, and metformin, the 90% CIs were all within the range of 0.8 - 1.25, which is the commonly accepted range for evaluating bioequivalence. Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Jun 2018 --> Apr 2019
- | Zemimet SR (gemigliptin/metformin sustained release) / LG Chem
Trial completion, Trial initiation date, Trial primary completion date: BE Study of the Combinations of Gemigliptin/Metformin HCl Extended Release 50/1000mg(25/500mg x 2 Tablets) in Comparison to Each Component Administered Alone (clinicaltrials.gov) - Feb 22, 2018
P1, N=70, Completed, Sponsor: LG Chem
Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Jun 2018 --> Apr 2019 Not yet recruiting --> Completed | Initiation date: Dec 2017 --> Dec 2017 | Trial primary completion date: Jan 2018 --> Jan 2018
- | Zemimet SR (gemigliptin/metformin sustained release) / LG Chem
New P1 trial: BE Study of the Combinations of Gemigliptin/Metformin HCl Extended Release 50/1000mg(25/500mg x 2 Tablets) in Comparison to Each Component Administered Alone (clinicaltrials.gov) - Nov 28, 2017
P1, N=70, Not yet recruiting, Sponsor: LG Chem
- | Zemimet SR (gemigliptin/metformin sustained release) / LG Chem
Trial primary completion date, Combination therapy: INTESTINE: Initial Combination of Gemigliptin and Metformin on Microbiota Change (clinicaltrials.gov) - Oct 9, 2017
P=N/A, N=70, Recruiting, Sponsor: Seoul National University Bundang Hospital
Not yet recruiting --> Completed | Initiation date: Dec 2017 --> Dec 2017 | Trial primary completion date: Jan 2018 --> Jan 2018 Trial primary completion date: Dec 2017 --> Jun 2018
- | Zemimet SR (gemigliptin/metformin sustained release) / LG Chem
Trial primary completion date, Combination therapy: INTESTINE: Initial Combination of Gemigliptin and Metformin on Microbiota Change (clinicaltrials.gov) - Feb 27, 2017
P=N/A, N=70, Recruiting, Sponsor: Seoul National University Bundang Hospital
Trial primary completion date: Dec 2017 --> Jun 2018 Trial primary completion date: Jun 2017 --> Dec 2017
- Zemimet SR (gemigliptin/metformin sustained release) / LG Chem
Trial primary completion date, Combination therapy: INTESTINE: Initial Combination of Gemigliptin and Metformin on Microbiota Change (clinicaltrials.gov) - Nov 28, 2016
P=N/A, N=70, Recruiting, Sponsor: Seoul National University Bundang Hospital
Trial primary completion date: Jun 2017 --> Dec 2017 Trial primary completion date: Dec 2016 --> Jun 2017
- | Zemimet SR (gemigliptin/metformin sustained release) / LG Chem
New P1 trial: BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 2000mg in Comparison to Each Component Administered Alone (clinicaltrials.gov) - Feb 1, 2016
P1, N=25, Enrolling by invitation, Sponsor: LG Life Sciences
- Zemimet SR (gemigliptin/metformin sustained release) / LG Chem
New trial, Combination therapy: INTESTINE: Initial Combination of Gemigliptin and Metformin on Microbiota Change (clinicaltrials.gov) - Nov 21, 2015
P=N/A, N=70, Recruiting, Sponsor: Seoul National University Bundang Hospital
- | Zemimet SR (gemigliptin/metformin sustained release) / LG Chem
Trial completion: BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered Alone. (clinicaltrials.gov) - May 6, 2014
P1, N=24, Completed, Sponsor: LG Life Sciences
Trial primary completion date: Dec 2016 --> Jun 2017 Not yet recruiting --> Completed
- | Zemimet SR (gemigliptin/metformin sustained release) / LG Chem
New P1 trial: BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered Alone. (clinicaltrials.gov) - Feb 4, 2014
P1, N=24, Not yet recruiting, Sponsor: LG Life Sciences
- | Zemimet SR (gemigliptin/metformin sustained release) / LG Chem
Trial completion: Food-Effect Bioavailability Study of FDC(Gemigliptin/Metformin HCl Sustained Release) 50/1000mg(25/500mg x 2tablets) (clinicaltrials.gov) - Oct 21, 2013
P1, N=24, Completed, Sponsor: LG Life Sciences
Not yet recruiting --> Completed Enrolling by invitation --> Completed
- | Zemimet SR (gemigliptin/metformin sustained release) / LG Chem
New P1 trial: Food-Effect Bioavailability Study of FDC(Gemigliptin/Metformin HCl Sustained Release) 50/1000mg(25/500mg x 2tablets) (clinicaltrials.gov) - Dec 9, 2012
P1, N=24, Completed, Sponsor: LG Life Sciences